LBPH vs. SAGE, PLRX, YMAB, TNGX, EOLS, SIGA, ARCT, COGT, PRTC, and AUPH
Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Sage Therapeutics (SAGE), Pliant Therapeutics (PLRX), Y-mAbs Therapeutics (YMAB), Tango Therapeutics (TNGX), Evolus (EOLS), SIGA Technologies (SIGA), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), PureTech Health (PRTC), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
Longboard Pharmaceuticals (NASDAQ:LBPH) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.
Longboard Pharmaceuticals has higher earnings, but lower revenue than Sage Therapeutics. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sage Therapeutics received 582 more outperform votes than Longboard Pharmaceuticals when rated by MarketBeat users. However, 73.33% of users gave Longboard Pharmaceuticals an outperform vote while only 67.82% of users gave Sage Therapeutics an outperform vote.
Longboard Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
Longboard Pharmaceuticals presently has a consensus price target of $43.67, suggesting a potential upside of 106.27%. Sage Therapeutics has a consensus price target of $37.67, suggesting a potential upside of 221.66%. Given Sage Therapeutics' higher possible upside, analysts clearly believe Sage Therapeutics is more favorable than Longboard Pharmaceuticals.
Longboard Pharmaceuticals has a net margin of 0.00% compared to Sage Therapeutics' net margin of -552.52%. Longboard Pharmaceuticals' return on equity of -49.87% beat Sage Therapeutics' return on equity.
In the previous week, Longboard Pharmaceuticals had 7 more articles in the media than Sage Therapeutics. MarketBeat recorded 9 mentions for Longboard Pharmaceuticals and 2 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 0.31 beat Longboard Pharmaceuticals' score of 0.01 indicating that Sage Therapeutics is being referred to more favorably in the news media.
63.3% of Longboard Pharmaceuticals shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 4.6% of Longboard Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Longboard Pharmaceuticals beats Sage Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Longboard Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longboard Pharmaceuticals Competitors List
Related Companies and Tools
